Patient characteristics
| . | BM/PB (n = 14 618) . | UCB (n = 6135) . | . | . | BM/PB (n = 14 618) . | UCB (n = 6135) . |
|---|---|---|---|---|---|---|
| Age | ||||||
| >55 y | 5 221 (35.7) | 2956 (48.2) | Donor type | MRD | 4 176 (28.6) | 0 (0.0) |
| 36-55 y | 6 336 (43.3) | 2235 (36.4) | MUD | 5 214 (35.7) | 0 (0.0) | |
| 16-35 y | 3 061 (20.9) | 944 (15.4) | MMUD | 3 046 (20.8) | 0 (0.0) | |
| Sex mismatch | ||||||
| FtoM | 2 994 (20.5) | 1749 (28.5) | 1 locus MMRD | 467 (3.2) | 0 (0.0) | |
| Others | 11 624 (79.5) | 4386 (71.5) | Haploidentical | 1 715 (11.7) | 0 (0.0) | |
| Disease | ||||||
| AML | 6 041 (41.3) | 3036 (49.5) | UCB | 0 (0.0) | 6135 (100.0) | |
| ALL | 2 949 (20.2) | 1033 (16.8) | Donor source | BM | 8 818 (60.3) | 0 (0.0) |
| MDS | 2 284 (15.6) | 830 (13.5) | PB | 5 800 (39.7) | 0 (0.0) | |
| MPN | 871 (6.0) | 231 (3.8) | UCB | 0 (0.0) | 6135 (100.0) | |
| ML | 2 372 (16.2) | 975 (15.9) | Conditioning | MAC | 9 592 (65.6) | 3776 (61.5) |
| MM | 101 (0.7) | 30 (0.5) | RIC | 5 026 (34.4) | 2359 (38.5) | |
| Disease risk index | ||||||
| Low | 1 104 (7.6) | 345 (5.6) | GVHD prophylaxis | CsA based | 4 000 (27.4) | 1192 (19.4) |
| Intermediate | 88 00 (60.2) | 3030 (49.4) | TAC based | 10 618 (72.6) | 4943 (80.6) | |
| High | 3 789 (25.9) | 2190 (35.7) | In vivo T-cell depletion | 1 969 (13.5) | 213 (3.5) | |
| Very high | 761 (5.2) | 526 (8.6) | SCT year | 2010-2015 | 7 056 (48.3) | 2261 (36.9) |
| HCT-CI | ||||||
| 0-1 | 11 235 (76.9) | 4430 (72.2) | 2016-2021 | 7 562 (51.7) | 3874 (63.1) | |
| ≥2 | 3 312 (22.7) | 1659 (27.0) |
| . | BM/PB (n = 14 618) . | UCB (n = 6135) . | . | . | BM/PB (n = 14 618) . | UCB (n = 6135) . |
|---|---|---|---|---|---|---|
| Age | ||||||
| >55 y | 5 221 (35.7) | 2956 (48.2) | Donor type | MRD | 4 176 (28.6) | 0 (0.0) |
| 36-55 y | 6 336 (43.3) | 2235 (36.4) | MUD | 5 214 (35.7) | 0 (0.0) | |
| 16-35 y | 3 061 (20.9) | 944 (15.4) | MMUD | 3 046 (20.8) | 0 (0.0) | |
| Sex mismatch | ||||||
| FtoM | 2 994 (20.5) | 1749 (28.5) | 1 locus MMRD | 467 (3.2) | 0 (0.0) | |
| Others | 11 624 (79.5) | 4386 (71.5) | Haploidentical | 1 715 (11.7) | 0 (0.0) | |
| Disease | ||||||
| AML | 6 041 (41.3) | 3036 (49.5) | UCB | 0 (0.0) | 6135 (100.0) | |
| ALL | 2 949 (20.2) | 1033 (16.8) | Donor source | BM | 8 818 (60.3) | 0 (0.0) |
| MDS | 2 284 (15.6) | 830 (13.5) | PB | 5 800 (39.7) | 0 (0.0) | |
| MPN | 871 (6.0) | 231 (3.8) | UCB | 0 (0.0) | 6135 (100.0) | |
| ML | 2 372 (16.2) | 975 (15.9) | Conditioning | MAC | 9 592 (65.6) | 3776 (61.5) |
| MM | 101 (0.7) | 30 (0.5) | RIC | 5 026 (34.4) | 2359 (38.5) | |
| Disease risk index | ||||||
| Low | 1 104 (7.6) | 345 (5.6) | GVHD prophylaxis | CsA based | 4 000 (27.4) | 1192 (19.4) |
| Intermediate | 88 00 (60.2) | 3030 (49.4) | TAC based | 10 618 (72.6) | 4943 (80.6) | |
| High | 3 789 (25.9) | 2190 (35.7) | In vivo T-cell depletion | 1 969 (13.5) | 213 (3.5) | |
| Very high | 761 (5.2) | 526 (8.6) | SCT year | 2010-2015 | 7 056 (48.3) | 2261 (36.9) |
| HCT-CI | ||||||
| 0-1 | 11 235 (76.9) | 4430 (72.2) | 2016-2021 | 7 562 (51.7) | 3874 (63.1) | |
| ≥2 | 3 312 (22.7) | 1659 (27.0) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CsA, cyclosporin; FtoM, female-to-male; HCT-CI, hematopoietic cell transplantation–specific comorbidity index; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; ML, malignant lymphoma; MM, multiple myeloma; MMRD, mismatched related donor; MMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; 1-locus MMRD, 1-locus mismatched related donor; RIC, reduced intensity conditioning; SCT, stem cell transplantation; TAC, tacrolimus.